Table 1.
Characteristics of the included trials
| Characteristics | No. (%) of papers (n = 125) |
|---|---|
| Cancer type | |
| Gastrointestinal | 21 (17) |
| Breast | 20 (16) |
| Genitourinary | 20 (16) |
| Lung | 16 (13) |
| Female reproductive organs | 13 (10) |
| Hematological | 11 (9) |
| Others | 23 (18) |
| Unknown | 1 (1) |
| Type I error (design) | |
| <0.05 | 6 (5) |
| 0.05 | 51 (41) |
| 0.1 | 38 (30) |
| >0.1 | 30 (24) |
| Power (design) | |
| <0.8 | 4 (3) |
| 0.80–0.84 | 78 (62) |
| 0.85–0.89 | 11 (9) |
| > = 0.9 | 32 (26) |
| Primary endpoint | |
| Progression-free survival | 84 (67) |
| Overall survival | 14 (11) |
| Objective response rate | 7 (6) |
| Disease-free survival; Recurrence-free survival; Event-free survival | 5 (4) |
| Complete response rate | 5 (4) |
| Co-primary endpoints | 5 (4) |
| Others | 5 (4) |